432 related articles for article (PubMed ID: 16521071)
1. [Calcimimetics].
Messa P; Como G; Brezzi B
G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Quarles LD
Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet: pharmacological and clinical aspects.
Messa P; Alfieri C; Brezzi B
Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1551-60. PubMed ID: 19040330
[TBL] [Abstract][Full Text] [Related]
5. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
6. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Vestergaard P; Nielsen LR; Mosekilde L
Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
8. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
Nagano N
Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
[TBL] [Abstract][Full Text] [Related]
9. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
10. Recent updates on the calcium-sensing receptor as a drug target.
Trivedi R; Mithal A; Chattopadhyay N
Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
12. Calcimimetic agents: review and perspectives.
Ureña P; Frazão JM
Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
[TBL] [Abstract][Full Text] [Related]
13. [Parathyroid and bone. Calcimimetics and bone metabolism].
Fukumoto S
Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
[TBL] [Abstract][Full Text] [Related]
14. [Calcimimetics--a new treatment for hyperparathyroidism?].
Piecha G; Chudek J; Wiecek A
Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
[TBL] [Abstract][Full Text] [Related]
15. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
[TBL] [Abstract][Full Text] [Related]
16. [Clinical application of calcimimetics].
Nishi H; Fukagawa M
Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
[TBL] [Abstract][Full Text] [Related]
17. Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review.
Ureña P
Artif Organs; 2003 Sep; 27(9):759-64. PubMed ID: 12940896
[TBL] [Abstract][Full Text] [Related]
18. [Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
Hanba Y; Ooura M; Negi S; Shigematsu T
Clin Calcium; 2008 Jan; 18(1):81-8. PubMed ID: 18175876
[TBL] [Abstract][Full Text] [Related]
19. [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
Sułowicz W
Przegl Lek; 2006; 63 Suppl 3():3-9. PubMed ID: 16898475
[TBL] [Abstract][Full Text] [Related]
20. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Almadén Y; Pineda C; Martínez-Moreno JM; Herencia C; Vergara N; Pendón-Ruiz de Mier MV; Santamaría R; Rodelo-Haad C; Casado-Díaz A; Lorenzo V; Carvalho C; Frazão JM; Felsenfeld AJ; Richards WG; Aguilera-Tejero E; Rodríguez M; López I; Muñoz-Castañeda JR
Kidney Int; 2019 May; 95(5):1064-1078. PubMed ID: 30878213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
